Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen's Q2 Revenues Rise 7 Percent, Aided by Currency

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market Monday that its second-quarter revenues increased 7 percent, or 1 percent on a constant exchange rate basis, "amid continued weak economic conditions."

The firm reported total sales of $282.2 million for the three-month period ended June 30, compared to $262.7 million for the second quarter of 2010. It beat analysts' consensus estimate of $279.4 million.

At constant exchange rates, Qiagen's molecular diagnostics sales increased 2 percent year over year as consumables growth was offset by lower instrument sales. Its applied testing sales increased 1 percent, as did its academia sales. The firm's pharma sales were "largely unchanged."

Qiagen posted adjusted net income of $55 million, or $.23 per share, up from $52.5 million, or $.22 per share. It beat the Wall Street estimate of $.22 per share for the quarter.

Qiagen's R&D spending increased 14 percent to $33 million from $29 million, and its SG&A expenses were up 11 percent at $99 million versus $89 million.

"We are making broad progress in our strategy to expand in 2011, a year that has proven to be more challenging than anticipated, in order to accelerate growth in 2012," Qiagen CEO Peer Schatz said in a statement. "We delivered improved results in the second quarter amid continued weak economic conditions."

During the quarter, Qiagen announced deals to acquire Australian biotech firm Cellestis for A$341 million ($355 million) in cash, and molecular diagnostics firm Ipsogen for €70 million ($101 million).

The firm also completed a submission with the US Food and Drug Administration for clearance of its therascreen KRAS RGQ assay for use as a companion diagnostic with an anticancer medicine. "We expect a second, separate FDA submission to be done shortly for this assay for use with another anticancer medicine," Schatz added.

For full-year 2011, Qiagen expects to report sales growth of 3 percent on a constant currency basis, which includes contributions from acquisitions. Its adjusted EPS is expected to be approximately $.96, which includes dilution of roughly $.03 per share related to planned investments and product migrations as part of the acquisitions of Cellestis and Ipsogen.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.